Table 1.

Cytotoxic Effect of Dexamethasone and Fludarabine on B-CLL Lymphocytes

Patient% Viability
No.ControlDexamethasoneFludarabine
99 ± 9 ND 54 ± 9 
102 ± 18 31 ± 2 28 ± 2 
65 ± 1.5 52 ± 1 27 ± 3 
29 ± 1 13 ± 0.2 7 ± 0.1 
55 ± 3 25 ± 2 21 ± 2 
25 ± 1 18 ± 1 15 ± 1 
83 ± 13 52 ± 12 37 ± 19 
69 ± 0.3 22 ± 0.3 26 ± 2 
65 ± 4 27 ± 0.4 32 ± 2 
10 100 ± 2.5 ND 32 ± 4 
11 68 ± 2 50 ± 0.3 25 ± 5 
Patient% Viability
No.ControlDexamethasoneFludarabine
99 ± 9 ND 54 ± 9 
102 ± 18 31 ± 2 28 ± 2 
65 ± 1.5 52 ± 1 27 ± 3 
29 ± 1 13 ± 0.2 7 ± 0.1 
55 ± 3 25 ± 2 21 ± 2 
25 ± 1 18 ± 1 15 ± 1 
83 ± 13 52 ± 12 37 ± 19 
69 ± 0.3 22 ± 0.3 26 ± 2 
65 ± 4 27 ± 0.4 32 ± 2 
10 100 ± 2.5 ND 32 ± 4 
11 68 ± 2 50 ± 0.3 25 ± 5 

B-CLL lymphocytes were incubated at 37°C for 48 hours in the absence of any factor (control) or with 10 μmol/L dexamethasone or fludarabine (5 μg/mL). Cell viability was determined by the MTT assay as described in Materials and Methods. Data are shown as the mean value ± SD.

Abbreviation: ND, not determined.

Close Modal

or Create an Account

Close Modal
Close Modal